



Unity in Diversity and the Standardisation of Clinical Pharmacy Services

Editors: Elida Zairina, Junaidi Khotib,
Chrismawan Ardianto, Syed Azhar Syed Sulaiman,
Charles D. Sands III and Timothy E. Welty

 CRC Press
Taylor & Francis Group
A BALKEMA BOOK

UNITY IN DIVERSITY AND THE STANDARDISATION OF CLINICAL
PHARMACY SERVICES



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

PROCEEDINGS OF THE 17TH ASIAN CONFERENCE ON CLINICAL PHARMACY (ACCP 2017),
28–30 JULY 2017, YOGYAKARTA, INDONESIA

Unity in Diversity and the Standardisation of Clinical Pharmacy Services

Editors

Elida Zairina

*Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga,
Surabaya, Indonesia*

Junaidi Khotib & Chrismawan Ardianto

*Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga,
Surabaya, Indonesia*

Syed Azhar Syed Sulaiman

*Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains
Malaysia, Penang, Malaysia*

Charles D. Sands III

*(Formerly) McWhorter School of Pharmacy, College of Health Sciences, Samford
University, Birmingham, Alabama, USA*

Timothy E. Welty

*Department of Clinical Sciences, College of Pharmacy and Health Sciences, Drake
University, Iowa, USA*



CRC Press

Taylor & Francis Group

Boca Raton London New York Leiden

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

A BALKEMA BOOK

CRC Press/Balkema is an imprint of the Taylor & Francis Group, an informa business

© 2018 Taylor & Francis Group, London, UK

Typeset by V Publishing Solutions Pvt Ltd., Chennai, India

Printed and bound in Great Britain by CPI Group (UK) Ltd, Croydon, CR0 4YY

All rights reserved. No part of this publication or the information contained herein may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, by photocopying, recording or otherwise, without written prior permission from the publisher.

Although all care is taken to ensure integrity and the quality of this publication and the information herein, no responsibility is assumed by the publishers nor the author for any damage to the property or persons as a result of operation or use of this publication and/or the information contained herein.

Published by: CRC Press/Balkema

Schipholweg 107C, 2316 XC Leiden, The Netherlands

e-mail: Pub.NL@taylorandfrancis.com

www.crcpress.com – www.taylorandfrancis.com

ISBN: 978-1-138-08172-7 (Hbk)

ISBN: 978-1-315-11275-6 (eBook)

Table of contents

Preface	ix
Organizing committee	xi
Keynote speakers	xv
Plenary speakers	xvii
List of symposium speakers	xix
Medication management system in several care homes in Surabaya <i>G.N.V. Achmad, G. Nugraheni, W. Utami, S. Hardiyanti, S. Danutri, D.K. Lestari, Muhliseh & A.T. Mahardika</i>	1
Effectiveness of decision aid on knowledge, decision conflict, and outcome in diabetic patients <i>L. Aditama & F. Yulia</i>	7
Self-esteem scale: Translation and validation in Malaysian adults living with asthma <i>S. Ahmad, M. Qamar, F.A. Shaikh, N.E. Ismail, A.I. Ismail & M.A.M. Zim</i>	13
Factors affecting mortality among patients undergoing hemodialysis in Sudan <i>O. Amir, A. Sarriff, A.H. Khan, M.B. Abdelraheem & B. Nors'adah</i>	19
Evaluating the effectiveness of filgrastim in patients with solid cancer <i>E.N. Anggraeny, F. Rahmawati & K.W. Taroeno-Hariadi</i>	27
Building care of hypertensive patients in reducing sodium intake in Banjarmasin <i>H. Ariyani, Akrom & R. Alfian</i>	33
Effect of glibenclamide on glycemic control in the presence of sodium diclofenac <i>T. Aryani, M.N. Zamzamah, Z. Izzah & M. Rahmadi</i>	41
A drug utilization study of antibiotics in patients with osteomyelitis <i>A.S. Budiatin, K.D. Kurdiana, B.S. Zulkarnain, H. Suroto & R. Diniya</i>	45
Factors influencing trastuzumab cardiotoxicity in breast cancer: A case–control study <i>C. Cherachat, C. Sukkasem, C. Somwangprasert, S. Pornbunjerd, N. Parinyanitikul & K. Tewthanom</i>	51
Transdermal patch loading diclofenac sodium for anti-inflammation therapy using a rat paw oedema model <i>P. Christanto, Isnaeni, A. Miatmoko & E. Hendradi</i>	55
Ethambutol-induced optic neuropathy in diabetic patients with tuberculosis <i>M. Djunaedi, U. Athiyah, Y. Priyandani & S.A.S. Sulaiman</i>	61
Identification of clinical specimens isolated from neonates <i>M. Djunaedi, S.A.S. Sulaiman, A. Sarriff, N.B.A. Aziz & Habsah</i>	65
Effect of coenzyme Q10 on the malondialdehyde level and exercise performance of male runners in Jakarta <i>S. Gunawan, Purwastyastuti, F.D. Suyatna & E.I. Ilyas</i>	73
Compatibility of selected inotropic drugs in a syringe <i>S. Hanifah, R.A. Kennedy & P.A. Ball</i>	81

Ward pharmacist workload analysis in an Indonesian class A hospital <i>A.L. Hariadini, W. Utami & A. Rahem</i>	87
Effect of LD50 of ethanolic leaf extract from <i>Ipomoea reptans</i> Poir. in rats <i>F. Hayati, R. Istikharah, S. Arifah & D. Nurhasanah</i>	95
Oral indomethacin versus oral paracetamol for patent ductus arteriosus closure in neonates <i>N.A. Ibrahim, N.C. Umar, M.C.H. Chi'ing, P.E. Stephen & P. Anandkrishnan</i>	99
Clinical trial of Jamu X on blood glucosa and HbA1C in patients with type 2 diabetes mellitus <i>Z. Ikawati, M. Eko Cahyanto, N.R. Sholehah & N. Atikah</i>	107
Management of carbamate or organophosphate intoxication at a high care unit <i>Z. Izzah, T. Aryani, R. Rodhika & Lestiono</i>	113
Development of an antidepressant e-learning tool for pharmacology education <i>A. Karaksha, M. Dharmesti, A.K. Davey, G. Grant, S.A. Dukie, H. Budianto, E.V. Mutiara, V. Marina, I. Puspitaningrum & A. Shollina</i>	119
Effectiveness of nimodipine on non-traumatic subarachnoid hemorrhage based on computed tomography angiography <i>J. Khotib, S.S. Ganesen & A.F. Sani</i>	125
Study of pediatric compounded drug prescriptions in a health care facility in Bandung <i>F. Lestari, Y. Aryanti & U. Yuniarni</i>	133
Efficacy of honey vinegar in hyperlipidemic rats (<i>Rattus norvegicus</i>) <i>E.W. Lucia, K. Lidya & T. Annisa</i>	139
Improving the competence of pharmacist students through international lecturers <i>O.R. Mafrihah, S. Hanifah, C.P. Sari, P.A. Ball & H. Morrissey</i>	143
The effectiveness evaluation of antiretroviral therapy in Mangusada Hospital Bali <i>H. Meriyani, N.N.W. Udayani & K.A. Adrianta</i>	149
Drug therapy problems in pediatric and geriatric patients at Farmasi Airlangga Pharmacy <i>Mufarrihah, D.M. Machfud, V.D.A. Purworini, A. Yuda, Y. Priyandani & Y. Nita</i>	153
PCR primer design for detection of SNPs in SLC22A1 rs683369 encoding OCT1 as the main transporter of metformin <i>A.A. Mukminatun, V.D.A. Ningrum & R. Istikharah</i>	161
Pharmacist-patient communication: An observational study of characteristic information <i>I. Mulyono, S. Irawati, A. Pratidina & M. Claramita</i>	167
Multidrug resistance-1 gene variants in pediatric leukemia in Bali <i>R. Niruri, N.L. Ulandari, S.C. Yowani, I. Narayani & K. Ariawati</i>	171
Medication adherence in the elderly with chronic diseases using the Adherence to Refill and Medication Scale (ARMS) <i>Y. Nita, F.M. Saputra, S. Damayanti, P.I. Pratiwi, R. Zukhairah, A. Sulistyarini & Y. Priyandani</i>	175
Direct non-medical costs of patients with cervical cancer who underwent chemotherapy <i>R. Noviyani, P.A. Indrayathi, H. Thabrany, Andrijono, I.N.G. Budiana & K. Tunas</i>	179
Factors influencing correct measurements of liquid medicines by consumers <i>G. Nugraheni & G.N.V. Achmad</i>	185
The correlation of service quality and complaint handling with patient satisfaction <i>R.A. Oetari, M.E. Sariwatin, H. Basir & C. Wiedyaningsih</i>	189
Assessment of medication safety among Filipino pharmacists <i>R.C. Ongpoy Jr., P.P. David, R.C. Ongpoy, M.D.U. Dean & A.D. Atienza</i>	195
Effect of the combination of <i>Typhonium flagelliforme</i> Lodd. (Blume) and <i>Phyllanthus niruri</i> Linn. on the immune system <i>S.S. Pangestika, A.P. Gani, A. Yuswanto & R. Murwanti</i>	201

Organophosphate toxicity in red chili farmers, Ciamis, Indonesia <i>D.A. Perwitasari, D. Prasasti, I.W. Arsanti & I.A. Wiraagni</i>	207
Factors affecting the rational use of NSAIDs in self-medication <i>L. Pristianty, G.N.V. Achmad & A. Faturrohmah</i>	213
The influence of adverse reactions of antituberculosis drugs to non-adherence in drug use <i>Y. Priyandani, C.D. Setiawan, A. Yuda, Y. Nita, U. Athiyah, M.B. Qomaruddin & Kuntoro</i>	217
(-)-Epigallocatechin gallate from green tea increases the level of a DNA repair enzyme <i>D.A. Purwanto</i>	223
Perceptions and practices of self-medication among healthcare students <i>M. Qamar, S. Norhazimah, F.A. Shaikh & S. Ahmad</i>	227
Smoking cessation counseling: Perceptions and barriers among community pharmacists <i>M. Qamar, S. Ahmad, K. Poobalan, F.A. Shaikh & M.A. Hammad</i>	233
Factors affecting medication noncompliance in patients with chronic diseases <i>A. Rahem</i>	241
The development and evaluation of a clinical pharmacy course at a pharmacy school in Indonesia <i>F. Rahmawati, D. Wahyono & M. Ihsan</i>	245
Relationship ejection fraction and segment ST-resolution in STEMI patients with streptokinase therapy <i>D.M.N. Ratri, S. Sjamsiah, H.P. Jaya & M. Aminuddin</i>	251
Management of hyponatremia in patients with heart failure: A retrospective study <i>S. Saepudin, P.A. Ball & H. Morrissey</i>	255
Continuous infusion versus intermittent bolus furosemide in heart failure NYHA III-IV <i>Samirah, S. Sjamsiah & M. Yogiarto</i>	261
The effectiveness of empirical and definitive antimicrobial therapy <i>I.P. Sari, R.H. Asdie, T. Nuryastuti, Sugiyono & Sumaryana</i>	265
<i>In vivo</i> analgesic effect of ethanolic extracts of exocarp, mesocarp, and seeds of <i>Carica pubescens</i> <i>H. Sasongko & Sugiyarto</i>	271
Evaluation of knowledge, attitude and perceived barriers towards adverse drug reaction reporting <i>F.A. Shaikh, S. Ahmad, E. Intra, M. Qamar & T.M. Khan</i>	275
Hydroxyethyl starch or gelatin, which is safer for the kidneys? <i>D.W. Shinta, J. Khotib, M. Rahmadi, B. Suprapti, E. Rahardjo & J.K. Wijoyo</i>	281
In silico QSAR of 1-benzoyl-3-benzylurea lead and its analogue compounds as anticancer <i>F. Suhud, C. Effendi & Siswando</i>	287
A study on antiemetics for postoperative nausea and vomiting at Dr. Soetomo Hospital <i>Suharjono, M.E.B.M.A. Nazim, B.P. Semedi & R. Diniya</i>	293
Ethanol extract of <i>Annona squamosa</i> L. improves the lipid profile in hyperlipidemia rats <i>R. Sumarny, Y. Sumiyati & D. Maulina</i>	297
The effect of Telmisartan on lipid levels and proinflammatory cytokines in ESRD patients undergoing hemodialysis <i>B. Suprapti, W.P. Nilamsari, Z. Izzah, M. Dhrik & B. Dharma</i>	303
Risk assessment of ADEs: Patient safety incident reports at Ari Canti Hospital in 2016 <i>D.A. Swastini, N.W.S. Wahyuni & K. Widiantara</i>	307
Medication-induced Adverse Drug Reaction (ADR) in the Malaysian elderly population <i>H.M. Taib, Z.A. Zainal, N.M. Ali & R. Hashim</i>	311

Cost-effectiveness analysis of patients with schizophrenia in Madani Hospital <i>M.R. Tandah, A. Mukaddas & W. Handayani</i>	317
Tacrolimus-induced symptomatic hyponatremia after kidney transplantation: A case study <i>T. Verayachankul & J. Tantivit</i>	323
Postoperative pain management in elderly patients: Evaluating the use of analgesics <i>A. Vonna, A. Apriani & Sadli</i>	327
Antimalarial activity and toxicological test of <i>Andrographis paniculata</i> tablets (AS202-01) <i>A. Widyawaruyanti, A.F. Hafid, D.A. Fitriningtyas, L.S. Lestari, H. Ilmi & I.S. Tantular</i>	333
Socioeconomic status and obesity in an adult rural population in Indonesia <i>A. Widayati, Fenty, D.M. Virginia & P. Hendra</i>	339
A strategic approach to increase the compliance of patients with type 2 diabetes mellitus <i>N. Wulandari, D. Viviandhari & Nurhayati</i>	343
Disposal practices of unused medication among the public in Meradong, Sarawak, Malaysia <i>N.L.C. Yaacob, L.P. Wei, S. Ahmad, F. Naimat & A. Ahmad</i>	349
Drug use and potential drug interaction in the elderly <i>A. Yuda, E.C. Dewi, D.M. Fami, L. Jamila, M. Rakhmawati, K.P.P. Sari, K.P. Ningrum, G.N.V. Achmad & Y. Nita</i>	357
Effects of audiovisual education on the knowledge and adherence of patients with DMT1 <i>L. Y. Yusan, N. Rochmah, A. Rahem & A. Purnamayanti</i>	363
Root extract of <i>Imperata cylindrica</i> L. improves serum nitric oxide levels in diabetic mice <i>A. Zada, J.B. Dewanto, A. Dahlan, D. Dhianawaty, M.R.A.A. Syamsunarno, G.R. Mukarromah & N. Anggraeni</i>	367
Medication use during pregnancy in Surabaya: A cross-sectional study <i>E. Zairina, G. Nugraheni, G.N. Veronika Ahmad, A. Yuda, Y. Nita, M.P. Wardhana & K.E. Gumilar</i>	371
Eyedrops use perception during fasting <i>B.S. Zulkarnain, Sumarno, Y. Nita & R. Loebis</i>	375
Author index	381

Robert K. Chalmers Distinguished Educator Award. He has also received the Russell R. Miller Literature Award and the Education Award from ACCP. In 2013 he was the national Rho Chi Distinguished Lecturer. Dr. DiPiro was elected a Fellow in the American Association for the Advancement of Science. Dr. DiPiro is a past Editor of The American Journal of Pharmaceutical Education. He is an editor for *Pharmacotherapy: A Pathophysiologic Approach*, now in its 10th edition. He is also the author of *Concepts in Clinical Pharmacokinetics* and Editor of the *Encyclopedia of Clinical Pharmacy*. He has published over 200 journal papers, books, book chapters, and editorials in academic and professional journals.



Prof. Charles F. Lacy—Professor of Pharmacy Practice and Vice President of Roseman University of Health Sciences, Henderson, Nevada, USA

Prof. Charles F. Lacy, Pharm.D., MS., FASHP, FCSHP, BCPP, CAATS is Professor of Pharmacy Practice and Vice-President of Roseman University of Health Sciences. He co-founded the university with his co-founders, Dr. Renee Coffman (President) and Dr. Harry Rosenberg (President emeritus). He has practiced clinical pharmacy and taught at numerous universities over the past 35 years. He was the Clinical Coordinator of Pharmacy Services at Cedars-Sinai for 20 years. He has specialized in numerous areas over the years, including psychiatric and neurologic pharmacy, oncology and informatics. He is the lead author of the renowned “Drug Information Handbook” and lead editor of the Lexi-Comp Clinical Reference Library. Dr. Lacy is a recognized leader in Pharmacy- he has worked with numerous Pharmacy & Therapeutics (P&T) Committees at the state and national level,

and has lead focus groups and task-forces in the areas of pharmacoeconomics, team building, complementary medicine, and medication therapy management throughout much of the world.

Plenary speakers



Prof. Michael D. Katz—*Professor at Department of Pharmacy Practice & Science, The University of Arizona College of Pharmacy, USA*

Prof. Michael D. Katz is Professor at the University of Arizona College of Pharmacy Department of Pharmacy Practice & Science. He practices at the University of Arizona Medical Center within the Department of Internal Medicine. His practice interests include general internal medicine, endocrinology, HIV/AIDS, infectious diseases, and evidence-based practice. Dr. Katz teaches pharmacy and medical students in both the classroom and experiential settings. He was selected in 2001 as a Dean's Teaching Scholar by the Arizona Health Sciences Center and has received numerous teaching awards. He is a Past-Chair of the American Society of Health-System Pharmacists (ASHP) Commission on Therapeutics. Dr. Katz has numerous publications and including *Pharmacotherapy Principles and Practices Study Guide: A Case-Based Care Plan Approach*, now in its fourth edition.

Dr. Katz is the Internal Medicine PGY2 Residency Program Director and directs all residency-related activities for the College of Pharmacy. He has been involved in international education and practice for even 15 years and he serves as the College of Pharmacy's Director of International Programs. In 2010 he received the University of Arizona's prestigious Excellence in International Education Award. He has consulted and lectured extensively in Japan and many other countries regarding pharmacy education and clinical pharmacy practice and he serves as the Co-Chair of the Board of Directors of the U.S—Thai Pharmacy Consortium. Dr. Katz directs the largest program of its kind to train clinical pharmacy faculty members from Saudi Arabia.



Dr. Umi Athiyah—*Al/Prof of Department of Pharmacy Practice and Dean of Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia*

Dr. Umi Athiyah is the current dean of Faculty of Pharmacy at University of Airlangga, Indonesia. Dr. Athiyah teaches various subjects including Pharmaceutical Philosophy, Community Pharmacy, Law and Ethics in Pharmacy, Management of Pharmacy Services and Logistics, Professional Communication, Pharmacoeconomics, Information Technology and Pharmaceutical Marketing. She has a research interest in Pharmacy Practice and Health Care System. She has been involved in many community based services. She has been invited as a speaker both in national and international conferences. She is one of the co-authors of a Pharmacy Management handbook.



Prof. Alan Lau—*Professor of Pharmacy Practice and Director of International Clinical Pharmacy Education at the University of Illinois at Chicago (UIC) College of Pharmacy, USA*

Prof. Alan Lau is Professor of Pharmacy Practice and Director of International Clinical Pharmacy Education at the University of Illinois at Chicago (UIC) College of Pharmacy. He obtained his Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees at the State University of New York at Buffalo and then completed a clinical pharmacy residency at UIC. He pioneered the development of clinical pharmacy services for renal failure patients on dialysis. Dr. Lau had obtained many research grants for clinical and laboratory research in renal pharmacotherapeutics and clinical pharmacology, with a recent focus on mineral and bone disorder in chronic kidney disease. He has published many research papers and book chapters, including chapters in the textbooks *Pharmacotherapy, Applied Therapeutics—*

The Clinical Use of Drugs and Basic Skills in Interpreting Laboratory Data. Dr. Lau was one of the founding members of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. In addition, he had served on the Board of Director and as Chairman of the Renal Scientific Section in the American Society for Clinical Pharmacology and Therapeutics. Dr. Lau was elected to be vice-chairman of the Nephrology/Urology Expert Committee of United States Pharmacopeia (USP) in 2007. In 2010, he was elected as a Distinguished Practitioner to the National Academies of Practice in Pharmacy. Since 2011, Dr. Lau has been working with the American College of Clinical Pharmacy on international program development and is now the International Program Director. He also has been appointed guest professor/faculty at the National Taiwan University, University of Hong Kong, University of Malta and also the Central South University in Changsha, China. Dr. Lau has been invited to give lectures on pharmacotherapy and clinical pharmacy service development in many countries, including Japan, South Korea, China, Hong Kong, Taiwan, Thailand, Vietnam, Malaysia, Singapore, Philippines, Indonesia, Saudi Arabia, Turkey and Malta.



Prof. Roger Lander—*Professor of Pharmacy Practice at Samford University, in Birmingham, Alabama, USA*

Prof. Roger Lander currently serves as Professor of Pharmacy Practice at Samford University, in Birmingham, Alabama, USA. He received his B.S. in Pharmacy and Pharm.D. from the University of Missouri-Kansas City and completed a clinical pharmacy residency program at Truman Medical Center. He then served as a faculty member at UMKC's Schools of Medicine and Pharmacy. Moving to Samford in 1986, he has developed practices in adult medicine, nutrition, ambulatory care, and pharmacokinetics. He previously served as Vice-Chair, Chair and Assistant Dean for Practice Programs. In 1994, Professor Lander helped develop a clerkship for Samford students at Guy's and St. Thomas' Hospitals in London and assisted the pharmacy there in the development of their ambulatory anticoagulation services. Professor Lander helped establish Samford's faculty/student

exchange program with Meijo University in Nagoya, Japan and has traveled widely throughout Asia for information exchange and to assist colleges and hospitals in their clinical teaching and practice. He helped develop study opportunities at Samford for pharmacists from England, Japan, Korea, China, Malaysia, Indonesia, and Vietnam. Dr. Lander is one of the founders of the Asian Conference on Clinical Pharmacy. He has traveled to Indonesia at least a dozen times to assist pharmacists in their practice development.

List of symposium speakers

SYMPOSIUM 1: DEVELOPING CLINICAL PHARMACY

- Prof. Charles D. Sands—*Former Dean and Professor (retired), McWhorter School of Pharmacy, College of Health Sciences, Samford University, Birmingham, Alabama, USA*
- Dr. Surakit Nathisuwan—*Associate Professor in Clinical Pharmacy in Clinical Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand*
- Ms. Nor Hasni Bt Haron—*Senior Principal Assistant Director Pharmaceutical Services Division, Ministry of Health of Malaysia*
- Dr. Budi Suprapti—*Al/Prof at Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga. Head of Pharmacy Department at Universitas Airlangga Teaching Hospital, Surabaya, Indonesia*
- Dr. Margaret Choye—*Clinical Assistant Professor at College of Pharmacy, the University of Illinois at Chicago, USA. Clinical Pharmacist in Internal Medicine at the University of Illinois at Chicago Hospital and Health System, USA*

SYMPOSIUM 2: ADVANCED PRACTICE 1

- Dr. Hiroyuki Kamei—*Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan*
- Dr. Hanna Sung—*University of the Pacific, Thomas J. Long, School of Pharmacy and Health Sciences in California, USA*
- Dr. Alexandre Chan—*Deputy Head and a tenured Associate Professor at the Department of Pharmacy, Faculty of Science at National University of Singapore (NUS) and the Duke-NUS Medical School, Singapore*
- Prof. Jae Wook Yang—*Professor and Director of the Institute of Clinical Research and Practice, College of Pharmacy, Sahmyook University & Vice President of Korean College of Clinical Pharmacy*
- Prof. Dr. Syed Azhar Syed Sulaiman—*Professor at School of Pharmaceutical Sciences at University Sains Malaysia, Penang, Malaysia*

SYMPOSIUM 3: MOLECULAR PHARMACOLOGY AND PHARMACOGENOMICS

- Dr. Mehdi Rajabi—*Clinical Pharmacy and Pharmacy Practice, Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, Iran. Clinical Pharmacist, Member of General Pharmaceutical Council of Great Britain*
- Mrs. Fan Zhang—*Lanzhou University, a Pharmacist-in-Charge at Pharmacy Department of the First Hospital of Lanzhou University in China*
- Dr. Lunawati Bennet—*Assoc. Professor of Pharmaceutical Sciences at Union University School of Pharmacy in Jackson, Tennessee, USA*
- Prof. Robert D. Sindelar—*Professor and former Dean of Faculty of Pharmaceutical Sciences, University of British Columbia; and Advisor, External relations, Centre for Health Evaluation & Outcomes Sciences (CHEOS), Providence Health Care research Institute and University of British Columbia, Canada*
- Dr. Baharudin Ibrahim—*School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia*

SYMPOSIUM 4: INTERPROFESSIONAL EDUCATION

- Dr. Christine B. Teng—*Assoc. Professor of Department of Pharmacy, National University of Singapore Principal Pharmacist (Clinical), Dept of Pharmacy, Tan Tock Seng Hospital, Singapore*
- Mr. Tan Wee Jin—*Principle Pharmacist at Guardian Health & Beauty, Singapore*
- Dr. Ching Jou Lim—*Senior lecturer in the Discipline of Social and Administrative Pharmacy, University Sains Malaysia, Malaysia*
- Mr. Mac Ardy J. Gloria—*University of the Philippines, The Philippines*
- Dr. Vivian Lee Wing Yan—*Assoc. Professor of the School of Pharmacy and the Assistant Dean (Student Development) of the Faculty of Medicine, Chinese University of Hong Kong*

SYMPOSIUM 5: ADVANCED PRACTICE 2

- Prof. Timothy E. Welty—*Professor and Chair of Clinical Science in the College of Pharmacy and Health Sciences at Drake University, Iowa, USA*
- Dr. Takao Shimazoe—*Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan*
- Prof. Zhou Quan—*Professor and Vice Dean of Department of Pharmacy, The Second Affiliated Hospital of Zhejiang University, China*
- Prof. Sukhyang Lee—*Professor of Clinical Pharmacy at College of Pharmacy, Ajou University, Korea*
- Prof. Kheirollah Gholami—*Professor and Chairman at the Department of Clinical Pharmacy, College of Pharmacy, Iran*

SYMPOSIUM 6: HEALTH CARE DELIVERY IN COMMUNITY PHARMACY

- Prof. Michael D. Hogue—*Assoc. Dean for the Center for Faith and Health at Samford University's College of Health Sciences, Birmingham, Alabama, USA*
- Dr. Elida Zairina—*Senior lecturer of Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia*
- Ms. Leonila M. Ocampo—*Chairman of the Hygieian Insitute for Education, research and Training Inc, The Philippines*
- Ms. Yong Pei Chean—*Senior Manager, Khoo Teck Puat Hospital and Council Member, Pharmaceutical Society of Singapore*
- Drs. Saleh Rustandi—*Chairman of Himpunan Seminari Farmasi Masyarakat (HISFARMA) of Indonesia*

SYMPOSIUM 7: PHARMACY EDUCATION

- Dr. Takashi Egawa—*Clinical Pharmaceutics and Health Sciences, Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan*
- Prof. Yolanda R. Robles—*Professor and former Dean College of Pharmacy, University of the Philippines*
- Prof. Rong-sheng Zhao—*Professor in Peking University Third Hospital, China. Assistant to President, Deputy-Director in Pharmacy Department of Peking University Third Hospital, China*
- Dr. Manit Saetewa—*Staff of Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Thailand*
- Drs. Nurul Falah Eddy Pariang—*President of Indonesian Pharmacist Association, Indonesia*
- Prof. Joseph T. Dipiro—*Dean, Professor and Archie O. McCalley Chair at the Virginia Commonwealth University, School of Pharmacy, Richmond, Virginia, USA*

SYMPOSIUM 8: ADVANCED PRACTICE 3

- Dr. Daraporn Rungprai—*Academic Staff of Faculty of Pharmacy, Silpakorn University, Thailand*
- Ms. Hong Yen NG—*President, 110th Council, Pharmaceutical Society of Singapore Specialist Pharmacist (Oncology), Singapore General Hospital*
- Prof. Agung Endro Nugroho—*Professor of Department of Pharmacology and Dean of Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia*

- Dr. Farshad Hashemian—*Assoc. Professor at Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, Iran*
- Dr. Junaidi Khotib—*Assoc. Professor of Department of Clinical Pharmacy at Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia*

SYMPOSIUM 9: IMPROVING PATIENT MEDICATION SAFETY

- Dr. Wimon Anansakunwatt—*Siriraj Hospital, Thailand*
- Mr. Mohammed Nazri Abdul Ghani—*Principal Pharmacist and Medication Safety Officer (MSO) of KK Women's & Children Hospital, Singapore*
- Ms. Yoon Sook Cho—*Director of Pharmacy Department, Seoul National University Hospital, Korea*
- Dr. Sutthiporn Pattharachayakul—*Assistant Professor at the Department of Clinical Pharmacy, Prince of Songkla University, Thailand*
- Dra Mariyatul Qibtiyah—*Head of Paediatric Pharmacy Services at Dr Soetomo Hospital, Surabaya, Indonesia*
- Prof. Charles F. Lacy—*Professor of Pharmacy Practice and Vice President of Roseman University of Health Sciences, Henderson, Nevada, USA*



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Continuous infusion versus intermittent bolus furosemide in heart failure NYHA III-IV

Samirah & S. Sjamsiah

Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

M. Yogiarto

Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Dr. Soetomo Hospital, Surabaya, Indonesia

ABSTRACT: The study was designed to investigate the therapeutic effect of Continuous Infusion (CI) and Intermittent Bolus (IB) administration of furosemide on patients with NYHA class III-IV heart failure hospitalized in Dr. Soetomo Hospital Surabaya. Thirteen patients received CI of furosemide and 10 patients received IB furosemide. Total urine output, net urine output (nUO/24 h) and urinary sodium excretion were monitored over 24 h. nUO/24 h of IB and CI were 1292 ± 299 mL and 2081 ± 637 mL, respectively. CI group showed significantly higher total urinary output than IB group (3399 ± 793 mL/24 h vs. 2556 ± 343 mL/24 h). The urinary sodium excretion of CI and IB were 302 ± 73 mmol/24 h and 228 ± 58 mmol/24 h, respectively. CI of furosemide resulted in higher total urinary output, net urinary output and urinary sodium excretion than IB furosemide in patients with NYHA class III and IV heart failure.

1 INTRODUCTION

Heart failure is a leading cause for hospitalization of patients older than 65 years. Patients are mostly admitted with dyspnea caused by volume overload. Intravenous loop diuretics are the main treatment for such patients (Palazzuoli et al. 2014). Intermittent bolus (IB) diuretics may cause rapid loss of intravascular volume. This can cause abnormality of electrolyte, renal dysfunction, activation of sympathetic nervous system (SNS) and renin angiotensin aldosterone system (RAAS). This stimulation increases renal sodium level, water resorption and plasma volume. Sympathetic excitation leads to peripheral vasoconstriction, arrhythmia, apoptosis and cardiac remodeling. On the other hand, continuous infusion (CI) can produce sustained and greater diuresis. Thus, intravascular volume fluctuation is minimum, avoiding wide swings in neurohormonal activation and electrolyte imbalance (Amer et al. 2012).

There have been several studies comparing loop diuretic intermittent bolus and continuous infusion; however the results are contradictory. A randomized, double-blind study of 308 subjects with ADHF, DOSE, compared high-dose versus low-dose and continuous versus intermittent infusion of furosemide. This study did not show positive outcome in either primary and secondary endpoints from regimen comparison. However, there was

higher rate of acute kidney injury in the high-dose group (Felker et al. 2011). This result is in line with a randomized study of 41 patients which concluded that there were no considerable differences (Allen et al. 2010). Another randomized, parallel-group study of 56 ADHF patients receiving furosemide compared continuous and intermittent administration. The study concluded that intermittent infusion of furosemide was well tolerated and significantly more effective than intermittent (Thompson et al. 2010). Despite wide use of furosemide in clinical practice, there is as yet no certain guideline to administer furosemide effectively (Salvador et al. 2005). Thus, this study is conducted to evaluate the efficacy and safety of intermittent bolus versus continuous infusion furosemide in a clinical setting.

2 MATERIAL AND METHOD

2.1 Study design

This was a single-center, prospective, consecutive study comparing continuous infusion (CI) versus intermittent bolus (IB) of furosemide in patients admitted to Dr. Soetomo Hospital, older than 30 years with clinical diagnosis of NYHA class III and IV heart failure. Ethical clearance was obtained from the ethical committee of Dr. Soetomo hospital. Patients were excluded if creatinine

serum levels were more than 2 mg/dL and if they received non-steroidal anti-inflammatory drugs, with exception of low dose aspirin (<325 mg). Patients were randomized into CI or IB group.

Total daily fluid balance was assessed for 24 h using flow sheets for each subject. Urinary sodium excretion was measured. Blood pressure was assessed three times daily. Electrolyte status and renal function were determined over 24 h. Doses of furosemide used were 60–120 mg.

2.2 Outcome measurement

The parameters of efficacy end point were net urine output, total urine output and urinary sodium excretion over 24 h. Net urine output is defined as urine output subtracted by oral plus intravenous (IV) fluid intake. Safety end point parameters were creatinine serum level to monitor the decrease in renal function. Sodium and potassium serum concentrations were assessed. Blood pressure was also monitored for hypotension observation.

2.3 Data analysis

All data were analyzed using independent t-test. Variables were presented as mean ± standard deviation and p value < 0,05 was considered significant.

3 RESULT AND DISCUSSION

A total of 23 patients were randomized. There were 10 patients receiving IB and 13 patients receiving CI of furosemide. Baseline characteristics of IB and CI group were not significantly different (Table 1).

Table 1. Baseline characteristics.

	Intermittent bolus (n = 10)	Continuous infusion (n = 13)
Age, mean ± SD (y)	51 ± 13	58 ± 9
Sex, n		
Female	4	4
Male	6	9
Other medication, n		
Spironolactone	9	6
ISDN	6	9
ACE Inhibitor	9	12
Digoxin	4	4
Coronary risk factor (%)		
DM	30	31
HT	60	54
CAD	10	15

Efficacy analysis was done by observing total urine output, net urine output and urinary sodium excretion for 24 h. The total urinary output/24 h in patients receiving IB and CI was 2,556 ± 344 mL and 3,399 ± 79 mL, respectively (p = 0.003; Fig. 1). Net urinary output/24 h of receiving IB and CI group was 1,292 ± 299 mL and 2,081 ± 637 mL, respectively (p = 0.0017; Fig. 1). The urinary sodium excretion/24 h in IB and CI group was 228 ± 58 mmol and 302 ± 73 mmol, respectively (p = 0.016; Fig. 2). Based on the result, there is significant difference in the total urinary output/24 h, the net urinary output/24 h and the urinary sodium excretion/24 h between CI and IB group.

Theoretically, CI of furosemide provides effective level of furosemide to inhibit Na/K/Cl transporter during infusion, resulting in increasing diuresis and natriuresis. Slow input of drug in CI increases secondary response produced by time-course drug delivery to the site of action. A low, but effective, concentration administered continuously increases diuretic effect of furosemide (Meyel 1992, Fergusson 1997, Wittstein 2006).

On the other hand, study by Aaser et al. (1997) found that there is no significant difference in 24 h




Figure 1. Efficacy end point showed by total urine output and net urine output after continuous infusion (CI) and intermittent bolus (IB) of furosemide.




Figure 2. Urinary sodium excretion with intermittent bolus vs. continuous infusion of furosemide.

urine output of patients receiving furosemide CI and IB. However, crossover studies show a greater diuresis in CI as compared to IB administration. A prospective randomized crossover study compared CI and single IV administration of furosemide on nine patients with NYHA class III and IV heart failure. Single dose of 30–40 mg/8 h was used. CI of furosemide was started by loading dose of 30–40 mg, continued with 2.5–3.3 mg/h for 48 h. The 48 h urine output after CI and single IV administration of furosemide was 2,865–6,365 mL (mean value = 3,790 mL) and 3,125–7,365 mL (mean value = 4,490 mL), respectively. Moreover, 48 h urinary sodium excretion for CI and single IV administration were 135–677 mEq and 115–547 mEq, respectively, indicating that 48 h urine output and urinary sodium excretion of CI are higher than single IV dose (Lahav et al. 1992). Another randomized crossover study on 20 patients compared efficacy of IV administration and 8 h infusion of furosemide. Dose used was 250–5,000 mg/24 h. The results showed that there was significant difference in 24 h urine output (CI vs. IV: 2860 ± 240 mL vs. 2660 ± 150 mL). Urinary sodium excretions in CI group and IV group were 210 ± 40 mmol and 150 ± 20 mmol, respectively. Additionally, there were five patients with reversible hearing problems in single dose IV group. Thus, CI might be more effective than single IV, and generated less ototoxicity (Dorman et al. 1996). Study in 56 patients evaluated effectiveness of CI versus intermittent infusion of furosemide and showed that patients receiving CI furosemide exhibit a greater diuresis as compared to those who received intermittent infusion (3,726 ± 1,121 mL/24 h vs. 2,955 ± 1,267 mL/24 h), respectively. This indicates that CI is safer and more effective than intermittent infusion (Thompson et al. 2010). Moreover, the result of the present study supports the previous study, showing that CI of furosemide is more effective than IB administration in patients with heart failure.

CI of furosemide produces less hemostatic effect, and no stimulation to RAAS, SNS and arginine vasopressin, resulting in a better drug response. On the other hand, IB increases renin and sympathetic response, so that the decline in plasma concentration of furosemide decreases blood pressure. However, the present study showed that there is no significant difference between CI and IB in all parameters of safety endpoint, systolic and diastolic blood pressure and heart rate (Table 2).

Single IV administration of furosemide leads to fluctuation of furosemide plasma level (Fergusson 1997). Furosemide can induce diuresis and natriuretic response when the concentration in tubules is adequate to block Na⁺/K⁺/2Cl⁻ transporter. There is post-diuretic sodium retention as a compensation mechanism when the urinary furosemide

level decreases, usually around 6 h post administration (Bruyne 2003, Ross et al. 2006). In single IV, natriuretic response and sodium retention will reduce the efficacy of furosemide (Fergusson 1997). Post-diuretic sodium retention is an acute diuretic resistance mediated by the activation of RAAS and SNS (Shankar et al. 2003, Wittstein 2006). Single IV dose produces massive diuresis and greater urine volume in a shorter time, leading to sudden decrease in intravascular volume. On the other hand, CI produces smaller reduction in intravascular volume, leading to the consistent increase in urine volume (Fergusson 1997, Bristow 2005).

A study compared furosemide, a short-acting loop diuretic, and azosemide, a long acting loop diuretic, to examine whether CI of furosemide could mimic the effect of long-acting loop diuretic. The report shows that furosemide gives a better improvement on heart rate variability than azosemide. This is due to the fact that furosemide, but not azosemide, stimulates renin release and SNS activity. Furthermore, furosemide, but not azosemide, inhibits the decrease in parasympathetic activity, which is commonly found in heart failure. The inhibition on the decreasing parasympathetic activity during heart failure protects the patient from cardiac sudden death event due to ventricular arrhythmia (Tomiyama et al. 1998).

In the present study, there was no difference in serum sodium, potassium and creatinine level attributed to the side effect of CI and IB administration of furosemide. This finding is in line with the study by Lahav et al. (1992) showing that there is no difference in side effect event. The result of other study evaluating the use of furosemide in patients with severe heart failure and renal insufficiency suggests that CI of furosemide is more effective and gives fewer side effects (Gerlag & Van Meijel 1988).

Table 2. Secondary end point.

	Intermittent bolus (n = 10)	Continuous infusion (n = 13)	p
Δ Systolic blood pressure (mmHg)	12 ± 18	12 ± 20	0.99
Δ Diastolic blood pressure (mmHg)	8 ± 18	17 ± 15	0.377
Δ Heart rate (beats/min)	13 ± 14	10 ± 13	0.508
Δ Serum sodium (mg/dL)	-2.7 ± 7.4	-6.8 ± 11.4	0.333
Δ Serum potassium (mg/dL)	0.3 ± 0.8	0.61 ± 0.9	0.467
Δ Serum creatinine (mg/dL)	0.01 ± 0.26	0.09 ± 0.50	0.647

4 CONCLUSION

The result of the present study suggests that CI of furosemide is more effective than IB administration in patients with NYHA class III and IV heart failure, as shown by the higher total urinary output, net urinary output and urinary sodium excretion after CI of furosemide. It is also suggested that furosemide, either by CI or BI administration, may not affect serum sodium, potassium and creatinine levels.

ACKNOWLEDGEMENT

This study was supported by a research grant from Faculty of Pharmacy, Universitas Airlangga.

REFERENCES

- Aaser, E. Gullestad, L., Tollofsrud, S. and Lundberg, J., 1997. Effect of bolus injection versus continuous infusion of furosemide on diuretics and neurohormonal activation in patients with severe congestive heart failure. *Scandinavian Journal of Clinical and Laboratory Investigation* 57: 361–368.
- Allen, L.A. Turer, A.T., DeWald, T., Stough, W.G., Cotter, G. & O'Connor, C.M., 2010. Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. *American Journal of Cardiology* 105: 188–193.
- Amer, M., Adomaityte, J. and Qayyum, R. 2012. Continuous infusion versus intermittent bolus furosemid in ADHF: an update meta-analysis of randomized control trials. *Journal of Hospital Medicines* 7(3).
- Bruyne, D. 2003, mechanisms and management of diuretic resistance in congestive heart failure. *Postgraduate Medical Journal* 79: 268–271.
- Dorman, T.P. & Gerlag, P.G. 1996. Combination of high dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. *European Heart Journal* 17: 1867–1874.
- Ferguson, J.A., Sundblad, K.J., Becker, P.K., Gorski, J.C., Rudy, D.W. & Brater, D.C., 1997. Role of duration of diuretic effect in preventing sodium retention. *Journal of Clinical Pharmacy and Therapeutics* 2(62): 203–208.
- Felker, G.M., Lee, K.L., Bull, D.A., Redfield, M.M., Stevenson, L.W., Goldsmith, S.R., LeWinter, M.M., Deswal, A., Rouleau, J.L., Ofili, E.O., Anstrom, K.J., Hernandez, A.F., McNulty, S.E., Velaquez, E.J., Kfoury, A.G., Chen, H.H., Gibertz, M.M., Semigran, M.J., Bart, B.A., Mascette, A.M., Braunwald, E. & O'Connor, C.M., 2011. Diuretic Strategies In Acute Decomposated Heart Failure. *New England Journal of Medicine* 364: 797–805.
- Gerlag, P.G. & Van Meijel, J.J., 1988. High Dose Furosemide in Treatment of Refractory Congestive Heart Failure. *Archives of Internal Medicines* 148: 286–291.
- Lahav, Regev, A. Raanani, P. & Thedor, E., 1992. Intermittent Administration of Furosemide vs. Continuous Infusion Preceded by Loading Dose for Congestive Heart Failure. *Chest* 102: 725–731.
- Meyel, J., 1992, Diuretic Efficiency of Furosemide During Continuous Administration Versus Bolus Injection in Healthy Volunteers. *Journal of Clinical Pharmacy and Therapeutics* 51: 440–444.
- Palazzouli, A., Pellegrini, M., Ruocco, G., Martini, G., Franci B., Campagna M., Gillemann M., Nuti R., McCullough, P.A. & Ronco, C., 2014. Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: A Prospective Randomized Trial. *Critical Care* 18: R134.
- Salvador, D.R., Rey, N.R., Ramos, G.C. & Punzalón, F.E., 2005. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. *Cochrane Database Systematic Review* 3: CD003178.
- Shankar, S., C. & Brater, D.C. 2003. Loop diuretika: from the Na-k 2 Cl transporter to clinical use. *American Journal of Physiology* 284: F11-F21.
- Thompsons, M., Nappi, J., Dunn, S., Hollis, I., Rodgers, J. & Van Bakel, A. 2010. Continuous versus intermittent infusion of furosemid in acute decompensated heart failure. *Journal of Cardiac Failure* 16(3):188–193.
- Tomiyama, H., Nakayama, T., Watanabe, G., Shiojima, K., Sakuma, Y., Yamamoto, A., Imai, Y., Yoshida, H. & Doba, N. 1999. Effect of short acting and long acting loop diuretics on heart rate variability in patient with chronic compensated congestive heart failure. *American Heart Journals* 137: 543–548.
- Wakelkamp, M., Alvian, G. & Gabriellsson, J. 1996. Pharmacodynamic modeling of furosemid tolerance after multiple intravenous administration. *Clinical Pharmacology and Therapeutics* 60(1): 75–88.
- Wittstein, I., 2006, *Diuretics*. In: *Baugman K. Baumgartner W, Treatment of Advanced Heart Failure*. New York: Taylor & Francis.

Author index

- Abdelraheem, M.B. 19
Achmad, G.N.V. 1, 185, 213, 357
Aditama, L. 7
Adrianta, K.A. 149
Ahmad, A. 349
Ahmad, S. 13, 227, 233, 275, 349
Akrom, 33
Alfian, R. 33
Ali, N.M. 311
Aminuddin, M. 251
Amir, O. 19
Anandakrishnan, P. 99
Andrijono, 179
Anggraeni, N. 367
Anggraeny, E.N. 27
Annisa, T. 139
Apriani, A. 327
Ariawati, K. 171
Arifah, S. 95
Ariyani, H. 33
Arsanti, I.W. 207
Aryani, T. 41, 113
Aryanti, Y. 133
Asdie, R.H. 265
Athiyah, U. 61, 217
Atienza, A.D. 195
Atikah, N. 107
Aziz, N.B.A. 65
- Ball, P.A. 81, 143, 255
Basir, H. 189
Budiana, I.N.G. 179
Budianto, H. 119
Budiatin, A.S. 45
- Cherachat, C. 51
Chi'ing, M.C.H. 99
Christanto, P. 55
Claramita, M. 167
- Dahlan, A. 367
Damayanti, S. 175
Danutri, S. 1
Davey, A.K. 119
- David, P.P. 195
Dean, M.D.U. 195
Dewanto, J.B. 367
Dewi, E.C. 357
Dharma, B. 303
Dharmesti, M. 119
Dhianawaty, D. 367
Dhrik, M. 303
Diniya, R. 45, 293
Djunaedi, M. 61, 65
Dukie, S.A. 119
- Effendi, C. 287
Eko Cahyanto, M. 107
- Fami, D.M. 357
Faturrohmah, A. 213
Fenty, 339
Fitripringtyas, D.A. 333
- Ganesen, S.S. 125
Gani, A.P. 201
Grant, G. 119
Gumilar, K.E. 371
Gunawan, S. 73
- Habsah, 65
Hafid, A.F. 333
Hammad, M.A. 233
Handayani, W. 317
Hanifah, S. 81, 143
Hardiyanti, S. 1
Hariadini, A.L. 87
Hashim, R. 311
Hayati, F. 95
Hendra, P. 339
Hendradi, E. 55
- Ibrahim, N.A. 99
Ihsan, M. 245
Ikawati, Z. 107
Ilmi, H. 333
Ilyas, E.I. 73
Indrayathi, P.A. 179
Intra, E. 275
Irawati, S. 167
- Ismail, A.I. 13
Ismail, N.E. 13
Isnaeni, 55
Istikharah, R. 95, 161
Izzah, Z. 41, 113, 303
- Jamila, L. 357
Jaya, H.P. 251
- Karaksha, A. 119
Kennedy, R.A. 81
Khan, A.H. 19
Khan, T.M. 275
Khotib, J. 125, 281
Kuntoro, 217
Kurdiana, K.D. 45
- Lestari, D.K. 1
Lestari, F. 133
Lestari, L.S. 333
Lestiono, 113
Lidya, K. 139
Loebis, R. 375
Lucia, E.W. 139
- Machfud, D.M. 153
Mafruhah, O.R. 143
Mahardika, A.T. 1
Marina, V. 119
Maulina, D. 297
Meriyani, H. 149
Miatmoko, A. 55
Morrissey, H. 143, 255
Mufarrihah, 153
Muhliseh, 1
Mukaddas, A. 317
Mukarromah, G.R. 367
Mukminatn, A.A. 161
Mulyono, I. 167
Murwanti, R. 201
Mutiar, E.V. 119
- Naimat, F. 349
Narayani, I. 171
Nazim, M.E.B.M.A. 293
Nilamsari, W.P. 303

- Ningrum, K.P. 357
 Ningrum, V.D.A. 161
 Niruri, R. 171
 Nita, Y. 153, 175, 217, 357, 371, 375
 Norhazimah, S. 227
 Norsa'adah, B. 19
 Noviyani, R. 179
 Nugraheni, G. 1, 185, 371
 Nurhasanah, D. 95
 Nurhayati, 343
 Nuryastuti, T. 265

 Oetari, R.A. 189
 Ongpoy Jr., R.C. 195
 Ongpoy, R.C. 195

 Pangestika, S.S. 201
 Parinyantikul, N. 51
 Perwitasari, D.A. 207
 Poobalan, K. 233
 Pornbunjerd, S. 51
 Prasasti, D. 207
 Pratidina, A. 167
 Pratiwi, P.I. 175
 Pristianty, L. 213
 Priyandani, Y. 61, 153, 175, 217
 Purnamayanti, A. 363
 Purwanto, D.A. 223
 Purwastyastuti, 73
 Purworini, V.D.A. 153
 Puspitaningrum, I. 119

 Qamar, M. 13, 227, 233, 275
 Qomaruddin, M.B. 217

 Rahardjo, E. 281
 Rahem, A. 87, 241, 363
 Rahmadi, M. 41, 281
 Rahmawati, F. 27, 245
 Rakhmawati, M. 357
 Ratri, D.M.N. 251
 Rochmah, N. 363
 Rodhika, R. 113

 Sadli, 327
 Saepudin, S. 255
 Samirah, 261
 Sani, A.F. 125
 Saputra, F.M. 175
 Sari, C.P. 143
 Sari, I.P. 265
 Sari, K.P.P. 357
 Sariwatin, M.E. 189
 Sarriff, A. 19, 65
 Sasongko, H. 271
 Semedi, B.P. 293
 Setiawan, C.D. 217
 Shaikh, F.A. 13, 227, 233, 275
 Shinta, D.W. 281
 Sholehah, N.R. 107
 Shollina, A. 119
 Siswandono, 287
 Sjamsiah, S. 251, 261
 Somwangprasert, C. 51
 Stephen, P.E. 99
 Sugiyarto, 271
 Sugiyono, 265
 Suharjono, 293
 Suhud, F. 287
 Sukkasem, C. 51
 Sulaiman, S.A.S. 61, 65
 Sulistyarini, A. 175
 Sumarno, 375
 Sumarny, R. 297
 Sumaryana, 265
 Sumiyati, Y. 297
 Suprapti, B. 281, 303
 Suroto, H. 45
 Suyatna, F.D. 73
 Swastini, D.A. 307
 Syamsunarno, M.R.A.A. 367

 Taib, H.M. 311
 Tandah, M.R. 317
 Tantivit, J. 323
 Tantular, I.S. 333
 Taroeno-Hariadi, K.W. 27
 Tewthanom, K. 51

 Thabrany, H. 179
 Tunas, K. 179

 Udayani, N.N.W. 149
 Ulandari, N.L. 171
 Umar, N.C. 99
 Utami, W. 1, 87

 Verayachankul, T. 323
 Veronika Ahmad, G.N. 371
 Virginia, D.M. 339
 Viviandhari, D. 343
 Vonna, A. 327

 Wahyono, D. 245
 Wahyuni, N.W.S. 307
 Wardhana, M.P. 371
 Wei, L.P. 349
 Widayati, A. 339
 Widiantara, K. 307
 Widyawaruyanti, A. 333
 Wiedyaningsih, C. 189
 Wijoyo, J.K. 281
 Wiraagni, I.A. 207
 Wulandari, N. 343

 Yaacob, N.L.C. 349
 Yogiarto, M. 261
 Yowani, S.C. 171
 Yuda, A. 153, 217, 357, 371
 Yulia, F. 7
 Yuniarni, U. 133
 Yusan, L.Y. 363
 Yuswanto, A. 201

 Zada, A. 367
 Zainal, Z.A. 311
 Zairina, E. 371
 Zamzamah, M.N. 41
 Zim, M.A.M. 13
 Zukhairah, R. 175
 Zulkarnain, B.S. 45, 375